Generex works on early diabetes test for children:
This article was originally published in Clinica
Executive Summary
Generex Biotechnology's subsidiary, Antigen Express, is developing a diagnostic kit for the early detection and screening of type 1 diabetes in young children. In a collaboration with two European diabetes centres, the company is to begin in vitro studies to identify the immune mechanisms that lead to the destruction of insulin-producing cells in the pancreas and to the onset of type 1 diabetes. The studies will focus on the role that lymphocytes play in a series of pancreatic antigens. Toronto, Canada-based Generex said that characterising these lymphocytes could lead to the development of a better screening parameter for those at risk of developing the disease, earlier diagnosis and possible intervention.